High-dimensional overfitting and noisy diagnostic labels: reconsidering the role of BRAF copy number in primary dermal melanoma.

Abstract

We address a fundamental ground-truth fallacy in the study's design: utilizing admittedly imperfect clinical diagnoses as the absolute standard to train classification models creates a circular logic. We propose that BRAF amplification in these cases more likely serves as a diagnostic corrective marker for misclassified dermal metastases, rather than a true prognostic indicator for isolated PDM.